Iterum Therapeutics reports Q3 non-GAAP EPS (16c) vs. (24c) last year

Reports Q3 revenue $390,000 vs. $0 last year. “We are thrilled to have launched ORLYNVAH in the United States in August 2025 for the treatment of uncomplicated urinary tract infections,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics (ITRM). “The significance of this milestone cannot be overstated-particularly given the importance of bringing a new treatment option to the uUTI space where antibiotic resistance continues to erode the efficacy of existing oral therapies and there have been no new branded launches for over 25 years. Given our limited commercial infrastructure and consistent with historical antibiotic launches, we anticipate modest sales in 2025. Looking ahead to 2026, as we continue to build momentum, we currently expect net product sales of ORLYNVAH to range between $5 million and $15 million, depending on uptake and payer coverage. We will continue to refine our guidance as market dynamics evolve over the next few quarters.”